Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00516139 · ClinicalTrials.gov registry record · Phase 3
Lamotrigine Extended-Release In Elderly Patients With Epilepsy
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 122
- Enrollment target
NCT00516139 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 122 participants.
The verdict
NCT00516139, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 122 participants
- Enrollment target
Study Summary
This study is being conducted to determine the safety and tolerability of lamotrigine (LTG) in elderly patients with epilepsy. This study will be carried out using an extended-release formulation of lamotrigine (LTG-XR) that will allow once-a-day dosing.
Interventions
- DRUG Lamotrigine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00516139
The ClinicalTrials.gov registry entry for NCT00516139 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lamotrigine is the first listed.
NCT00516139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00516139 about?
NCT00516139 is a clinical study titled "Lamotrigine Extended-Release In Elderly Patients With Epilepsy". This study is being conducted to determine the safety and tolerability of lamotrigine (LTG) in elderly patients with epilepsy. This study will be carried out using an extended-release formulation of lamotrigine (LTG-XR) that will allow once-a-day dosing.
What is the current status of trial NCT00516139?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 122 participants. The study started on 2007-08. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00516139?
The interventions under investigation include: Lamotrigine (DRUG).
Who is sponsoring clinical trial NCT00516139?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.